Managerial workarounds in three European DRG systems.


Journal

Journal of health organization and management
ISSN: 1758-7247
Titre abrégé: J Health Organ Manag
Pays: England
ID NLM: 101179473

Informations de publication

Date de publication:
08 Feb 2020
Historique:
entrez: 5 5 2020
pubmed: 5 5 2020
medline: 9 3 2021
Statut: ppublish

Résumé

Attempts to transform health systems have in many countries involved starting to pay healthcare providers through a DRG system, but that has involved managerial workarounds. Managerial workarounds have seldom been analysed. This paper does so by extending and modifying existing knowledge of the causes and character of clinical and IT workarounds, to produce a conceptualisation of the managerial workaround. It further develops and revises this conceptualisation by comparing the practical management, at both provider and purchaser levels, of hospital DRG payment systems in England, Germany and Italy. We make a qualitative test of our initial assumptions about the antecedents, character and consequences of managerial workarounds by comparing them with a systematic comparison of case studies of the DRG hospital payment systems in England, Germany and Italy. The data collection through key informant interviews ( Managers in all three countries developed very similar workarounds to contain healthcare costs to payers. To weaken DRG incentives to increase hospital activity, managers agreed to lower DRG payments for episodes of care above an agreed case-load 'ceiling' and reduced payments by less than the full DRG amounts when activity fell below an agreed 'floor' volume. Empirically this study is limited to three OECD health systems, but since our findings come from both Bismarckian (social-insurance) and Beveridge (tax-financed) systems, they are likely to be more widely applicable. In many countries, DRGs coexist with non-DRG or pre-DRG systems, so these findings may also reflect a specific, perhaps transient, stage in DRG-system development. Probably there are also other kinds of managerial workaround, yet to be researched. Doing so would doubtlessly refine and nuance the conceptualisation of the 'managerial workaround' still further. In the case of DRGs, the managerial workarounds were instances of 'constructive deviance' which enabled payers to reduce the adverse financial consequences, for them, arising from DRG incentives. The understanding of apparent failures or part-failures to transform a health system can be made more nuanced, balanced and diagnostic by using the concept of the 'managerial workaround'. Managerial workarounds also appear outside the health sector, so the present analysis of managerial workarounds may also have application to understanding attempts to transform such sectors as education, social care and environmental protection. So far as we are aware, no other study presents and tests the concept of a 'managerial workaround'. Pervasive, non-trivial managerial workarounds may be symptoms of mismatched policy objectives, or that existing health system structures cannot realise current policy objectives; but the workarounds themselves may also contain solutions to these problems.

Identifiants

pubmed: 32364346
doi: 10.1108/JHOM-10-2019-0295
pmc: PMC7406989
doi:

Types de publication

Journal Article

Langues

eng

Pagination

295-311

Subventions

Organisme : Department of Health
ID : 08/1806/262
Pays : United Kingdom

Informations de copyright

© Rod Sheaff, Verdiana Morando, Naomi Chambers, Mark Exworthy, Ann Mahon, Richard Byng and Russell Mannion.

Références

Sociol Health Illn. 2015 Mar;37(3):404-21
pubmed: 25581280
Int J Aging Hum Dev. 2009;68(1):65-92
pubmed: 19348105
BMC Health Serv Res. 2013 May 11;13:175
pubmed: 23663305
Sociol Health Illn. 2010 Mar;32(3):452-69
pubmed: 20415790
J Am Med Inform Assoc. 2008 Jan-Feb;15(1):114-9
pubmed: 17947626
BMJ. 2013 Jun 07;346:f3197
pubmed: 23747967
Health Serv Res. 1999 Apr;34(1 Pt 2):405-15
pubmed: 10199684
Int J Integr Care. 2012 Jan-Mar;12:e16
pubmed: 22977429
Health Aff (Millwood). 2012 Feb;31(2):426-33
pubmed: 22323174
Eur J Health Econ. 2017 Mar;18(2):139-153
pubmed: 26831045
Health Policy. 2017 Feb;121(2):119-125
pubmed: 27908564
Lancet. 2002 Jun 8;359(9322):2027-9
pubmed: 12076573
Int J Integr Care. 2010 Jun 23;10:e046
pubmed: 20689772
Health Care Manage Rev. 2008 Jan-Mar;33(1):2-12
pubmed: 18091439
Health Care Manag Sci. 2006 Aug;9(3):215-23
pubmed: 17016927
N Engl J Med. 2012 Mar 22;366(12):1075-7
pubmed: 22435368
J Am Med Inform Assoc. 2008 Jul-Aug;15(4):408-23
pubmed: 18436903
Health Policy. 2013 Mar;109(3):290-300
pubmed: 23069132
J Health Econ. 2015 Sep;43:13-26
pubmed: 26114589
Health Policy. 2007 Dec;84(2-3):308-20
pubmed: 17574699
Accid Anal Prev. 2009 Jul;41(4):739-54
pubmed: 19540963
Qual Saf Health Care. 2005 Feb;14(1):56-60
pubmed: 15692005
Health Policy. 2013 Jan;109(1):14-22
pubmed: 23062311
BMJ Qual Saf. 2017 Jul;26(7):542-551
pubmed: 27129493
Health Commun. 2017 Aug;32(8):1004-1013
pubmed: 27463257
Int J Med Inform. 2007 Jun;76 Suppl 1:S98-103
pubmed: 16807084
Int J Med Inform. 2013 May;82(5):e161-9
pubmed: 23083928

Auteurs

Rod Sheaff (R)

School of Law, Criminology and Government, Plymouth University, Plymouth, UK.

Verdiana Morando (V)

CERGAS Research Centre, SDA Bocconi Scuola di Direzione Aziendale, Milano, Lombardia, Italy.
GSD Healthcare, Dubai, United Arab Emirates.

Naomi Chambers (N)

Alliance Manchester Business School, The University of Manchester, Manchester, UK.

Mark Exworthy (M)

University of Birmingham, Birmingham, UK.

Ann Mahon (A)

Alliance Manchester Business School, The University of Manchester, Manchester, UK.

Richard Byng (R)

Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth University, Plymouth, UK.

Russell Mannion (R)

University of Birmingham, Birmingham, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH